Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim prophylaxis with topotecan in advanced gynecologic malignancies
2007-006069-34Phase 2Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2007
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim and topotecan in ovarian cancer, Cervical Cancer (CC) and endometrial cancer (EC), sponsored by Policlinico Gemelli. Primary endpoints: Mobilization of peripheral blood cell populations, Serum cytokine levels and 1 more. Started Nov 2007; status: terminated.
02
Drugs
pegfilgrastimtopotecan
03
Conditions
ovarian cancerCervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on 2007-006069-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006069-34.